Aquestive prices $85M common stock offering of 21.25M shares at $4.00/share

Aquestive Therapeutics, Inc.

Offers 21.25M shares at $4.00/share; expected gross proceeds $85M, closing Aug 15, 2025.
Proceeds to primarily fund launch/commercialization of Anaphylm (epinephrine sublingual film) pending FDA approval.
Offering led by RTW Investments; includes Samsara BioCapital, EcoR1 Capital, Perceptive Advisors, others.
Joint bookrunning managers: Leerink Partners, Cantor, Oppenheimer; H.C. Wainwright lead manager.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.